Acute Respiratory Distress Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
The acute respiratory distress syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects.
Key Targets in the Acute Respiratory Distress Syndrome Pipeline Market
The key targets in the acute respiratory distress syndrome pipeline market are ADP Ribosylation Factor 6, Angiopoietin 1 Receptor, Dipeptidase 1, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, 2019 Novel corona Virus Spike Glycoprotein, and 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase. ADP Ribosylation Factor 6 has the highest number of pipeline products.
Acute Respiratory Distress Syndrome Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Acute Respiratory Distress Syndrome Pipeline Market
The key MoA in the acute respiratory distress syndrome pipeline market are ADP Ribosylation Factor 6 Inhibitor, Dipeptidase 1 Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, 2019 Novel corona Virus Spike Glycoprotein Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, and Alpha 1 Antitrypsin Replacement. ADP Ribosylation Factor 6 Inhibitor has the highest number of pipeline products.
Acute Respiratory Distress Syndrome Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Acute Respiratory Distress Syndrome Pipeline Market
The key RoA in the acute respiratory distress syndrome pipeline market are intravenous, oral, inhalational, parenteral, subcutaneous, intraarticular, and intraperitoneal. Intravenous has the highest number of pipeline products.
Acute Respiratory Distress Syndrome Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Type in the Acute Respiratory Distress Syndrome Pipeline Market
The key molecule type in the acute respiratory distress syndrome pipeline market are small molecule, cell therapy, biologic, peptide, gene-modified cell therapy, monoclonal antibody, synthetic peptide, oligonucleotide, and recombinant protein. Small molecule has the highest number of pipeline products in the acute respiratory distress syndrome pipeline market.
Acute Respiratory Distress Syndrome Pipeline Market, by Molecule Type
For more molecule type insights, download a free report sample
Key Companies in the Acute Respiratory Distress Syndrome Pipeline Market
The key companies in the acute respiratory distress syndrome pipeline market are Bayer AG, BioStem Technologies Inc, Pantherna Therapeutics GmbH, A6 Pharmaceuticals LLC, Arch Biopartners Inc, Athersys Inc, Faron Pharmaceuticals Oy, and Meridigen Biotech Co Ltdz. Bayer AG has the highest number of pipeline products.
Acute Respiratory Distress Syndrome Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
| Key targets | ADP Ribosylation Factor 6, Angiopoietin 1 Receptor, Dipeptidase 1, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, 2019 Novel corona Virus Spike Glycoprotein, and 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase |
| Key MoA | ADP Ribosylation Factor 6 Inhibitor, Dipeptidase 1 Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, 2019 Novel corona Virus Spike Glycoprotein Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, and Alpha 1 Antitrypsin Replacement |
| Key RoA | Intravenous, Oral, Inhalational, Parenteral, Subcutaneous, Intraarticular, and Intraperitoneal |
| Key molecule type | Small Molecule, Cell Therapy, Biologic, Peptide, Gene-Modified Cell Therapy, Monoclonal Antibody, Synthetic Peptide, Oligonucleotide, and Recombinant Protein |
| Key companies | Bayer AG, BioStem Technologies Inc, Pantherna Therapeutics GmbH, A6 Pharmaceuticals LLC, Arch Biopartners Inc, Athersys Inc, Faron Pharmaceuticals Oy, and Meridigen Biotech Co Ltdz |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Abbreos Inc
AcelRx Pharmaceuticals Inc
Akttyva Therapeutics Inc
Alveolus Bio Inc
AMNICELL Corp Ltd
Ampio Pharmaceuticals Inc
APEIRON Biologics AG
ARBORMED Pharmaceuticals Inc
Arch Biopartners Inc
Athersys Inc
Avalon GloboCare Corp
Aviceda Therapeutics
AVM Biotechnology LLC
Bayer AG
Biocon Ltd
BioMarck Pharmaceuticals Ltd
BioStem Technologies Inc
Bioxytran Inc
Bonus BioGroup Ltd
Cartesian Therapeutics Inc
Cellular Biomedicine Group Ltd
Cellvation Inc
Celularity Inc
Curacle Co Ltd
Cytonus Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Dianomi Therapeutics Inc
Emergent BioSolutions Inc
Endece LLC
Enlivex Therapeutics Ltd
Eunoia Biotech LLC
Exvastat Ltd
Faron Pharmaceuticals Oy
GentiBio Inc
Green Cross LabCell Corp
Grifols SA
Haisco Pharmaceutical Group Co Ltd
Histocell SL
ImmunityBio Inc
Implicit Bioscience Ltd
Imstem Biotechnology Inc
In2cure AB
IsletOne AB
Kalvista Pharmaceuticals Inc
Kubota Vision Inc
Kyorin Pharmaceutical Co Ltd
Liminal BioSciences Inc
LTT Bio-Pharma Co Ltd
MannKind Corp
MDI Therapeutics Inc
MediPost Co Ltd
Medsenic SAS
Meridigen Biotech Co Ltd
Nano Biotherapeutics Inc
Neutrolis Inc
Northern Therapeutics Inc
NS Pharma Inc
Nuvara Therapeutics LLC
OGB1 Inc
Omnispirant Ltd
Orion Biotechnology Canada Ltd
Pantherna Therapeutics GmbH
PharmAbcine Inc
Restore Therapeutics LLC
RION Health Inc
Shanghai Henlius Biotech Inc
SolAeroMed Inc
Sorrento Therapeutics Inc
Systimmune Inc
Thetis Pharmaceuticals LLC
Vasomune Inc
Veru Inc
Windtree Therapeutics Inc
Xfibra Inc
Xintela AB
ZyVersa Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the acute respiratory distress syndrome pipeline market?
The key targets in the acute respiratory distress syndrome pipeline market are ADP Ribosylation Factor 6, Angiopoietin 1 Receptor, Dipeptidase 1, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, 2019 Novel corona Virus Spike Glycoprotein, and 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase.
-
What are the key MoA in the acute respiratory distress syndrome pipeline market?
The key MoA in the acute respiratory distress syndrome pipeline market are ADP Ribosylation Factor 6 Inhibitor, Dipeptidase 1 Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, 2019 Novel corona Virus Spike Glycoprotein Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, and Alpha 1 Antitrypsin Replacement.
-
What are the key RoA in the acute respiratory distress syndrome pipeline market?
The key RoA in the acute respiratory distress syndrome pipeline market are intravenous, oral, inhalational, parenteral, subcutaneous, intraarticular, and intraperitoneal.
-
What are the key molecule type in the acute respiratory distress syndrome pipeline market?
The key molecule type in the acute respiratory distress syndrome pipeline market are small molecule, cell therapy, biologic, peptide, gene-modified cell therapy, monoclonal antibody, synthetic peptide, oligonucleotide, and recombinant protein.
-
What are the key companies in the acute respiratory distress syndrome pipeline market?
The key companies in the acute respiratory distress syndrome pipeline market are Bayer AG, BioStem Technologies Inc, Pantherna Therapeutics GmbH, A6 Pharmaceuticals LLC, Arch Biopartners Inc, Athersys Inc, Faron Pharmaceuticals Oy, and Meridigen Biotech Co Ltdz.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Acute Respiratory Distress Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Respiratory reports